Status:
COMPLETED
Drug Exposure Registry for GSK2248761, an Investigational NNRTI
Lead Sponsor:
ViiV Healthcare
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
HIV Infections
Eligibility:
All Genders
Brief Summary
The World Health Organization has estimated that as many as 10% of the population worldwide may at some point experience at least one seizure. The percentage with active epilepsy is from 0.4% to 1%. F...
Detailed Description
The objective of the study is to collect and monitor data on all subjects who previously received GSK2248761 while enrolled in the Phase 2b studies SGN113399 or SGN113404 evaluating GSK2248761. There ...
Eligibility Criteria
Inclusion
- Subjects who were previously randomized in the Phase 2b studies SGN113399 or SGN113404 and received GSK2248761
Exclusion
- N/A
Key Trial Info
Start Date :
July 29 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2013
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT01458132
Start Date
July 29 2011
End Date
April 30 2013
Last Update
September 11 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.